AbbVie

RemeGen lands major licensing deal

RemeGen scores out-licensing triple play with AbbVie deal

The agreement marks the drug maker’s third such transaction since last year, setting records for both its largest upfront payment and highest total deal value Key Takeaways: PD-1/VEGF bispecific antibodies…
9995.HK
688331.SHG
BeiGene has a total of three marketed proprietary products.

FAST NEWS: Beigene stock falls after Novartis terminates partnership

The latest: Cancer drug maker BeiGene Ltd. (BGNE.US; 6160.HK; 668235.SH) announced Tuesday that Novartis (NOVN.SWX) will relinquish its rights to co-develop, produce and commercialize BeiGene’s esophagus cancer drug tislelizumab. Looking up: Novartis will provide…
BGNE.US
6160.HK
BeiGene was slapped with a patent lawsuit by U.S. rival AbbVie in June, and suffered another blow to its global ambitions in July when Novartis pulled out of a drug collaboration.

Sales success comes with side effects for drug maker BeiGene

The Chinese biotech’s product revenues surged nearly 82% in the second quarter, driven by forecast-beating sales of its core cancer drugs Key Takeaways: Global sales of BeiGene's anti-tumor drug zanubrutinib…
BGNE.US
6160.HK

Recent Articles

RELATED ARTICLES

  1. Jacobio Pharma turn profit
    Jacobio Pharma poised to turn a profit from precision cancer drugs
  2. Big deal, bigger doubts: CSPC slides after $18.5 billion pact
  3. InSilico lands drug discovery deal after Hong Kong IPO
    3696.HK
  4. BRIEF: Everest Medicines advances with major licensing deal, new drug application approval
    1952.HK
  5. Ming Yu seeks a share of the drug sector limelight
  6. Lagging in the weight-loss market? Take Fosun’s GLP-1 pill
    2196.HK
    600196.SHG
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva